AU Patent

AU2023219845B2 — Crystalline forms of 3-(imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-N- {4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide mono hydrochloride

Assigned to Takeda Pharmaceuticals USA Inc · Expires 2025-03-20 · 1y expired

What this patent protects

C:\Interwo n\NRPortbl\DCC\SXD\938646 l.docx-4/l0/2019 ABSTRACT Novel crystalline forms of 3-(imidazo[1,2-b]pyridazin-3-yethynyl)-4-methyl-N-{4 [(4methylpiperazin- 1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide mono hydrochloride and to methods of their preparation are disclo…

USPTO Abstract

C:\Interwo n\NRPortbl\DCC\SXD\938646 l.docx-4/l0/2019 ABSTRACT Novel crystalline forms of 3-(imidazo[1,2-b]pyridazin-3-yethynyl)-4-methyl-N-{4 [(4methylpiperazin- 1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide mono hydrochloride and to methods of their preparation are disclosed herein.

Drugs covered by this patent

Patent Metadata

Patent number
AU2023219845B2
Jurisdiction
AU
Classification
—
Expires
2025-03-20
Drug substance claim
No
Drug product claim
No
Assignee
Takeda Pharmaceuticals USA Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.